Human β-defensin 4 with non-native disulfide bridges exhibit antimicrobial activity

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Sharma, Himanshu ^a   Nagaraj, Ramakrishnan ^a  

^a CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN 4; CYSTEINE; NUCLEIC ACID; OMEGA CONOTOXIN; ANTIINFECTIVE AGENT; BETA DEFENSIN; CONOTOXIN; DEFB4A PROTEIN, HUMAN; DISULFIDE; PEPTIDE;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIA; CANDIDA ALBICANS; CELL DEATH; CONTROLLED STUDY; CYTOSOL; DISULFIDE BOND; NONHUMAN; PROTEIN SECONDARY STRUCTURE; AMINO ACID SEQUENCE; CHEMISTRY; DRUG EFFECTS; ESCHERICHIA COLI; GROWTH, DEVELOPMENT AND AGING; HUMAN; INNATE IMMUNITY; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MOLECULAR GENETICS; PSEUDOMONAS AERUGINOSA; SOLID PHASE SYNTHESIS; STAPHYLOCOCCUS AUREUS; SYNTHESIS; ULTRASTRUCTURE;

CANDIDA ALBICANS;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BETA-DEFENSINS; CANDIDA ALBICANS; CONOTOXINS; CYTOSOL; DISULFIDES; ESCHERICHIA COLI; HUMANS; IMMUNITY, INNATE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN STRUCTURE, SECONDARY; PSEUDOMONAS AERUGINOSA; SOLID-PHASE SYNTHESIS TECHNIQUES; STAPHYLOCOCCUS AUREUS;

EID: 84925780409     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119525     Document Type: Article

References (75)

1. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003; 3: 710-720. PMID: 12949495
2. Wehkamp J, Schmid M, Fellermann K, Stange EF. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. J Leukoc Biol. 2005; 77: 460-465. PMID: 15618294
3. Selsted ME, Ouellette AJ. Mammalian defensins in the antimicrobial immune response. Nat Immunol. 2005; 6: 551-557. PMID: 15908936
4. Semple F, Dorin JR. beta-Defensins: multifunctional modulators of infection, inflammation and more? J Innate Immun. 2012; 4: 337-348. doi: 10.1159/000336619 PMID: 22441423
5. Schneider JJ, Unholzer A, Schaller M, Schafer-Korting M, Korting HC. Human defensins. J Mol Med (Berl). 2005; 83: 587-595. PMID: 15821901
6. Pazgier M, Hoover DM, Yang D, Lu W, Lubkowski J. Human beta-defensins. Cell Mol Life Sci. 2006; 63: 1294-1313. PMID: 16710608
7. Hill CP, Yee J, Selsted ME, Eisenberg D. Crystal structure of defensin HNP-3, an amphiphilic dimer: mechanisms of membrane permeabilization. Science. 1991; 251: 1481-1485. PMID: 2006422
8. Hoover DM, Rajashankar KR, Blumenthal R, Puri A, Oppenheim JJ, Chertov O, et al. The structure of human beta-defensin-2 shows evidence of higher order oligomerization. J Biol Chem. 2000; 275: 32911-32918. PMID: 10906336
9. Hoover DM, Chertov O, Lubkowski J. The structure of human beta-defensin-1: new insights into structural properties of beta-defensins. J Biol Chem. 2001; 276: 39021-39026. PMID: 11486002
10. Schibli DJ, Hunter HN, Aseyev V, Starner TD, Wiencek JM, McCray PB, et al. The solution structures of the human beta-defensins lead to a better understanding of the potent bactericidal activity of HBD3 against Staphylococcus aureus. J Biol Chem. 2002; 277: 8279-8289. PMID: 11741980
11. Selsted ME, Harwig SS. Determination of the disulfide array in the human defensin HNP-2. A covalently cyclized peptide. J Biol Chem. 1989; 264: 4003-4007. PMID: 2917986
12. Tang YQ, Selsted ME. Characterization of the disulfide motif in BNBD-12, an antimicrobial betadefensin peptide from bovine neutrophils. J Biol Chem. 1993; 268: 6649-6653. PMID: 8454636
13. Tang YQ, Yuan J, Osapay G, Osapay K, Tran D, Miller CJ, et al. A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins. Science. 1999; 286: 498-502. PMID: 10521339
14. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell. 1997; 88: 553-560. PMID: 9038346
15. Harder J, Bartels J, Christophers E, Schroder JM. A peptide antibiotic from human skin. Nature. 1997; 387: 861. PMID: 9202117
16. Harder J, Bartels J, Christophers E, Schroder JM. Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem. 2001; 276: 5707-5713. PMID: 11085990
17. Garcia JR, Krause A, Schulz S, Rodriguez-Jimenez FJ, Kluver E, Adermann K, et al. Human beta-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. FASEB J. 2001; 15: 1819-1821. PMID: 11481241
18. Ericksen B, Wu Z, Lu W, Lehrer RI. Antibacterial activity and specificity of the six human alpha-defensins. Antimicrob Agents Chemother. 2005; 49: 269-275. PMID: 15616305
19. Mandal M, Nagaraj R. Antibacterial activities and conformations of synthetic alpha-defensin HNP-1 and analogs with one, two and three disulfide bridges. J Pept Res. 2002; 59: 95-104. PMID: 11985703
20. Wu Z, Hoover DM, Yang D, Boulegue C, Santamaria F, Oppenheim JJ, et al. Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human beta-defensin 3. Proc Natl Acad Sci U S A. 2003; 100: 8880-8885. PMID: 12840147
21. Hoover DM, Wu Z, Tucker K, Lu W, Lubkowski J. Antimicrobial characterization of human beta-defensin 3 derivatives. Antimicrob Agents Chemother. 2003; 47: 2804-2809. PMID: 12936977
22. Maemoto A, Qu X, Rosengren KJ, Tanabe H, Henschen-Edman A, Craik DJ, et al. Functional analysis of the alpha-defensin disulfide array in mouse cryptdin-4. J Biol Chem. 2004; 279: 44188-44196. PMID: 15297466
23. Sharma H, Nagaraj R. Antimicrobial activity of human beta-defensin 4 analogs: insights into the role of disulfide linkages in modulating activity. Peptides. 2012; 38: 255-265. doi: 10.1016/j.peptides.2012.08.024 PMID: 23000475
24. Thennarasu S, Nagaraj R. Synthetic peptides corresponding to the beta-hairpin loop of rabbit defensin NP-2 show antimicrobial activity. Biochem Biophys Res Commun. 1999; 254: 281-283. PMID: 9918829
25. Kluver E, Schulz-Maronde S, Scheid S, Meyer B, Forssmann WG, Adermann K. Structure-activity relation of human beta-defensin 3: influence of disulfide bonds and cysteine substitution on antimicrobial activity and cytotoxicity. Biochemistry. 2005; 44: 9804-9816. PMID: 16008365
26. Krishnakumari V, Singh S, Nagaraj R. Antibacterial activities of synthetic peptides corresponding to the carboxy-terminal region of human beta-defensins 1-3. Peptides. 2006; 27: 2607-2613. PMID: 16860904
27. Terlau H, Olivera BM. Conus venoms: a rich source of novel ion channel-targeted peptides. Physiol Rev. 2004; 84: 41-68. PMID: 14715910
28. Norton RS, Olivera BM. Conotoxins down under. Toxicon. 2006; 48: 780-798. PMID: 16952384
29. Lewis RJ, Dutertre S, Vetter I, Christie MJ. Conus venom peptide pharmacology. Pharmacol Rev. 2012; 64: 259-298. doi: 10.1124/pr.111.005322 PMID: 22407615
30. Daly NL, Craik DJ. Structural studies of conotoxins. IUBMB Life. 2009; 61: 144-150. doi: 10.1002/iub.158 PMID: 19165896
31. Lancelin JM, Kohda D, Tate S, Yanagawa Y, Abe T, Satake M, et al. Tertiary structure of conotoxin GIIIA in aqueous solution. Biochemistry. 1991; 30: 6908-6916. PMID: 2069951
32. Nielsen KJ, Watson M, Adams DJ, Hammarstrom AK, Gage PW, Hill JM, et al. Solution structure of muconotoxin PIIIA, a preferential inhibitor of persistent tetrodotoxin-sensitive sodium channels. J Biol Chem. 2002; 277: 27247-27255. PMID: 12006587
33. Yao S, Zhang MM, Yoshikami D, Azam L, Olivera BM, Bulaj G, et al. Structure, dynamics, and selectivity of the sodium channel blocker mu-conotoxin SIIIA. Biochemistry. 2008; 47: 10940-10949. doi: 10.1021/bi801010u PMID: 18798648
34. Jacob RB, McDougal OM. The M-superfamily of conotoxins: a review. Cell Mol Life Sci. 2010; 67: 17-27. doi: 10.1007/s00018-009-0125-0 PMID: 19705062
35. Khoo KK, Feng ZP, Smith BJ, Zhang MM, Yoshikami D, Olivera BM, et al. Structure of the analgesic mu-conotoxin KIIIA and effects on the structure and function of disulfide deletion. Biochemistry. 2009; 48: 1210-1219. doi: 10.1021/bi801998a PMID: 19170536
36. Han TS, Zhang MM, Walewska A, Gruszczynski P, Robertson CR, Cheatham TE, et al. Structurally minimized mu-conotoxin analogues as sodium channel blockers: implications for designing conopeptide-based therapeutics. ChemMedChem. 2009; 4: 406-414. doi: 10.1002/cmdc.200800292 PMID: 19107760
37. Khoo KK, Gupta K, Green BR, Zhang MM, Watkins M, Olivera BM, et al. Distinct disulfide isomers of mu-conotoxins KIIIA and KIIIB block voltage-gated sodium channels. Biochemistry. 2012; 51: 9826-9835. doi: 10.1021/bi301256s PMID: 23167564
38. Atherton E, Sheppard RC. Solid Phase Peptide Synthesis: A practical Approach: Oxford University Press; 1989.
39. Weber PJ, Bader JE, Folkers G, Beck-Sickinger AG. A fast and inexpensive method for N-terminal fluorescein-labeling of peptides. Bioorg Med Chem Lett. 1998; 8: 597-600. PMID: 9871567
40. Tam JP, Wu CR, Liu W, Zhang JW. Disulfide Bond Formation in Peptides by Dimethyl-Sulfoxide-Scope and Applications. J Am Chem Soc. 1991; 113: 6657-6662.
41. Schulz A, Kluver E, Schulz-Maronde S, Adermann K. Engineering disulfide bonds of the novel human beta-defensins hBD-27 and hBD-28: differences in disulfide formation and biological activity among human beta-defensins. Biopolymers. 2005; 80: 34-49. PMID: 15625724
42. MacDonald RC, MacDonald RI, Menco BP, Takeshita K, Subbarao NK, Hu LR. Small-volume extrusion apparatus for preparation of large, unilamellar vesicles. Biochim Biophys Acta. 1991; 1061: 297-303. PMID: 1998698
43. Ishitsuka R, Yamaji-Hasegawa A, Makino A, Hirabayashi Y, Kobayashi T. A lipid-specific toxin reveals heterogeneity of sphingomyelin-containing membranes. Biophys J. 2004; 86: 296-307. PMID: 14695271
44. Fishov I, Woldringh CL. Visualization of membrane domains in Escherichia coli. Mol Microbiol. 1999; 32: 1166-1172. PMID: 10383758
45. Xu Z, Zhong Z, Huang L, Peng L, Wang F, Cen P. High-level production of bioactive human beta-defensin-4 in Escherichia coli by soluble fusion expression. Appl Microbiol Biotechnol. 2006; 72: 471-479. PMID: 16437202
46. White SH, Wimley WC, Selsted ME. Structure, function, and membrane integration of defensins. Curr Opin Struct Biol. 1995; 5: 521-527. PMID: 8528769
47. Bohling A, Hagge SO, Roes S, Podschun R, Sahly H, Harder J, et al. Lipid-specific membrane activity of human β-Defensin-3. Biochemistry. 2006; 45: 5663-5670. PMID: 16634647
48. Lourenzoni MR, Namba AM, Caseli L, Degreve L, Zaniquelli ME. Study of the interaction of human defensins with cell membrane models: Relationships between structure and biological activity. J Phys Chem B. 2007; 111: 11318-11329. PMID: 17784741
49. Dowhan W. Molecular basis for membrane phospholipid diversity: Why are there so many lipids? Ann Rev Biochem. 1997; 66: 199-232. PMID: 9242906
50. Murzyn K, Rog T, Pasenkiewicz-Gierula M. Phosphatidylethanolamine-phosphatidylglycerol bilayer as a model of the inner bacterial membrane. Biophys J. 2005; 88: 1091-1103. PMID: 15556990
51. Lehrer RI, Lichtenstein AK, Ganz T. Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Annu Rev Immunol. 1993; 11: 105-128. PMID: 8476558
52. Xie C, Prahl A, Ericksen B, Wu Z, Zeng P, Li X, et al. Reconstruction of the conserved beta-bulge in mammalian defensins using D-amino acids. J Biol Chem. 2005; 280: 32921-32929. PMID: 15894545
53. Zhang Y, Lu W, Hong M. The membrane-bound structure and topology of a human alpha-defensin indicate a dimer pore mechanism for membrane disruption. Biochemistry. 2010; 49: 9770-9782. doi: 10. 1021/bi101512j PMID: 20961099
54. Liu S, Zhou L, Li J, Suresh A, Verma C, Foo YH, et al. Linear analogues of human beta-defensin 3: concepts for design of antimicrobial peptides with reduced cytotoxicity to mammalian cells. Chembiochem. 2008; 9: 964-973. doi: 10.1002/cbic.200700560 PMID: 18350527
55. Mandal M, Jagannadham MV, Nagaraj R. Antibacterial activities and conformations of bovine beta-defensin BNBD-12 and analogs:structural and disulfide bridge requirements for activity. Peptides. 2002; 23: 413-418. PMID: 11835989
56. Tietze AA, Tietze D, Ohlenschlager O, Leipold E, Ullrich F, Kuhl T, et al. Structurally diverse mu-conotoxin PIIIA isomers block sodiumchannel NaV 1.4. Angew Chem Int Ed Engl. 2012; 51: 4058-4061. doi: 10. 1002/anie.201107011 PMID: 22407516
57. Schmidt NW, Mishra A, Lai GH, Davis M, Sanders LK, Tran D, et al. Criterion for amino acid composition of defensins and antimicrobial peptides based on geometry of membrane destabilization. J Am Chem Soc. 2011; 133: 6720-6727. doi: 10.1021/ja200079a PMID: 21473577
58. Schmidt NW, Tai KP, Kamdar K, Mishra A, Lai GH, Zhao K, et al. Arginine in alpha-defensins: differential effects on bactericidal activity correspond to geometry of membrane curvature generation and peptide-lipid phase behavior. J Biol Chem. 2012; 287: 21866-21872. doi: 10.1074/jbc.M112.358721 PMID: 22566697
59. Zou G, de Leeuw E, Li C, Pazgier M, Zeng P, Lu WY, et al. Toward understanding the cationicity of defensins. J Biol Chem. 2007; 282: 19653-19665. PMID: 17452329
60. Circo R, Skerlavaj B, Gennaro R, Amoroso A, Zanetti M. Structural and functional characterization of hBD-1(Ser35), a peptide deduced from a DEFB1 polymorphism. Biochem Biophys Res Commun. 2002; 293: 586-592. PMID: 12054642
61. Morgera F, Antcheva N, Pacor S, Quaroni L, Berti F, Vaccari L, et al. Structuring and interactions of human beta-defensins 2 and 3 with model membranes. J Pept Sci. 2008; 14: 518-523. PMID: 18085509
62. Saberwal G, Nagaraj R. Cell-lytic and antibacterial peptides that act by perturbing the barrier function of membranes: facets of their conformational features, structure-function correlations and membrane-perturbing abilities. Biochim Biophys Acta. 1994; 1197: 109-131. PMID: 8031824
63. Matsuzaki K. Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochim Biophys Acta. 1999; 1462: 1-10. PMID: 10590299
64. Shai Y. Mode of action of membrane active antimicrobial peptides. Biopolymers. 2002; 66: 236-248. PMID: 12491537
65. Lehrer RI, Barton A, Daher KA, Harwig SS, Ganz T, Selsted ME. Interaction of human defensins with Escherichia coli. J Clin Invest. 1989; 84: 553-561. PMID: 2668334
66. Wimley WC, Selsted ME, White SH. Interactions between human defensins and lipid bilayers: evidence for formation of multimeric pores. Protein Sci. 1994; 3: 1362-1373. PMID: 7833799
67. Sawai MV, Jia HP, Liu L, Aseyev V, Wiencek JM, McCray PB, et al. The NMR structure of human beta-defensin-2 reveals a novel alpha-helical segment. Biochemistry. 2001; 40: 3810-3816. PMID: 11300761
68. Bauer F, Schweimer K, Kluver E, Conejo-Garcia JR, Forssmann WG, Rosch P, et al. Structure determination of human and murine beta-defensins reveals structural conservation in the absence of significant sequence similarity. Protein Sci. 2001; 10: 2470-2479. PMID: 11714914
69. de Leeuw E, Li C, Zeng P, Diepeveen-de Buin M, Lu WY, Breukink E, et al. Functional interaction of human neutrophil peptide-1 with the cell wall precursor lipid II. FEBS Lett. 2010; 584: 1543-1548. doi: 10.1016/j.febslet.2010.03.004 PMID: 20214904
70. Sass V, Schneider T, Wilmes M, Korner C, Tossi A, Novikova N, et al. Human beta-defensin 3 inhibits cell wall biosynthesis in Staphylococci. Infect Immun. 2010; 78: 2793-2800. doi: 10.1128/IAI.00688-09 PMID: 20385753
71. Park CB, Kim HS, Kim SC. Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun. 1998; 244: 253-257. PMID: 9514864
72. Subbalakshmi C, Sitaram N. Mechanism of antimicrobial action of indolicidin. FEMS Microbiol Lett. 1998; 160:91-96. PMID: 9495018
73. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 2005; 3: 238-250. PMID: 15703760
74. Vermeer LS, Lan Y, Abbate V, Ruh E, Bui TT, Wilkinson LJ, et al. Conformational flexibility determines selectivity and antibacterial, antiplasmodial, and anticancer potency of cationic alpha-helical peptides. J Biol Chem. 2012; 287: 34120-34133. doi: 10.1074/jbc.M112.359067 PMID: 22869378
75. Maria-Neto S, Candido Ede S, Rodrigues DR, de Sousa DA, da Silva EM, de Moraes LM, et al. Deciphering the magainin resistance process of Escherichia coli strains in light of the cytosolic proteome. Antimicrob Agents Chemother. 2012; 56: 1714-1724. doi: 10.1128/AAC.05558-11 PMID: 22290970